Mengmeng (Margaret) Du, ScD, MSc

Associate Attending Epidemiologist

Mengmeng (Margaret) Du, ScD, MSc

Associate Attending Epidemiologist
Share
Share
Mengmeng (Margaret) Du, Assistant Attending Epidemiologist

Office Phone

646-227-3495

Education

Harvard University

Current Research Interests

Dr. Du works with international teams to reduce the burden of endometrial, colorectal, and pancreatic cancers, focusing on underserved populations with poor outcomes. She studies tumor biology and risk profiles, with the goal of identifying those who may benefit from risk-reducing education, lifestyle changes, or early detection. She leads the Data Coordinating Center and co-chairs the Executive Committee for E2C2 (Epidemiology of Endometrial Cancer Consortium), where she studies the twofold higher endometrial cancer mortality in Black women. She studies colorectal cancer genomics and risk factors in diverse populations, including Nigeria through ARGO (African Research Group for Oncology). She leads the MSK Pancreatic Tumor Registry, which studies the causes of pancreatic cancer and conducts screening and risk evaluation. She also studies telomere dynamics in several data sources. Her work is funded by the NCI, NCATS, David M. Rubenstein Center for Pancreatic Cancer Research, and philanthropic sources.

Dr. Du is committed to scientific education and training. She co-directs MSK’s QSURE (Quantitative Sciences Undergraduate Research Experience) program and mentors trainees. She holds a joint appointment as Associate Professor at Weill Cornell Medicine, where she teaches Foundations of Epidemiology. She serves on the MSK Research Council, the NYC Epidemiology Forum Scientific Committee, and as Associate Editor for Cancer Causes & Control.

Publications

Representative Publications

  1. Risk prediction models for endometrial cancer: development and validation in an international consortium. Joy Shi, Peter Kraft, Bernard Rosner, …, Herbert Yu, Mengmeng Du (joint senior author), Immaculata De Vivo (joint senior author). J Natl Cancer Inst. 2023;djad014. doi: 10.1093/jnci/djad014. Online ahead of print.
  2. Healthcare utilization, cancer screening and potential barriers to accessing cancer care in rural South West Nigeria: a cross-sectional study. Avinash Sharma, Olusegun Isaac Alatise, Kelli O’Connell, …, Olalekan Olasehinde, T Peter Kingham, Mengmeng Du. BMJ Open. 2021;11(7):e040352.
  3. Evaluation of early-life factors and early-onset colorectal cancer among men and women in the UK Biobank. Valerie Gausman (joint lead author), Peter S Liang (joint lead author), Kelli O’Connell, Elizabeth D Kantor, Mengmeng Du. Gastroenterology. 2022;162(3):981-983.e3.
  4. Association between polycystic ovary syndrome and pancreatic cancer risk. Noah C. Peeri (joint lead author), Marco V. Landicino (joint lead author), C. Amethyst Saldia, Robert C. Kurtz, Vineet S. Rolston, Mengmeng Du. JAMA Oncology. 2022. doi: 10.1001/jamaoncol.2022.4540.
  5. Shorter telomeres associate with a reduced risk of melanoma development. Hongmei Nan (joint lead author), Mengmeng Du (joint lead author), Immaculata De Vivo, …, Abrar A Qureshi, David J Hunter, Jiali Han. Cancer Research. 2011;71(21):6758-63.

View a full listing of Mengmeng (Margaret) Du’s journal articles.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Mengmeng (Margaret) Du discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures